The anthracycline drug doxorubicin is among the most used—and useful—
chemotherapeutics. While doxorubicin is highly effective in the treatment of various …

Acute Myeloid Leukemia | NEJM Skip to main content NEJM Group Follow Us Facebook Twitter
Instagram YouTube LinkedIn Prepare to become a physician, build your knowledge, lead a …

Natural killer (NK) cells are an emerging cellular immunotherapy for patients with acute
myeloid leukemia (AML); however, the best approach to maximize NK cell antileukemia …

CD47 is a widely expressed cell surface protein that functions as a regulator of phagocytosis
mediated by cells of the innate immune system, such as macrophages and dendritic cells …

Acute myeloid leukemia (AML) is a heterogeneous clonal disorder characterized by
immature myeloid cell proliferation and bone marrow failure. Cytogenetics and mutation …

Patients with acute myeloid leukaemia who relapse following therapy have few treatment
options and face poor outcomes. Immune checkpoint inhibition, for example, by antibody …

Cancer is widely characterized by the sequential acquisition of genetic lesions in a single
lineage of cells. Our previous studies have shown that, in acute myeloid leukemia (AML) …

Cancer is one of the major diseases threatening human life and health worldwide.
Epigenetic modification refers to heritable changes in the genetic material without any …

Given that most bone marrow cells are short-lived, the accumulation of multiple
leukemogenic mutations in a single clonal lineage has been difficult to explain. We propose …

In 2003, an international working group last reported on recommendations for diagnosis,
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …